Oruka Therapeutics (NASDAQ:ORKA) Insider Joana Goncalves Sells 7,000 Shares

Key Points

• Insider sale: Director Joana Goncalves sold 7,000 shares on April 15 at an average of $66.12 for $462,840, reducing her stake by 17.34% to 33,377 shares; the trade was executed under a pre‑arranged Rule 10b5‑1 plan.
• Market action: ORKA slid about 2.3% to $65.55 on heavy volume (~1.4M shares vs. a 658k average), trading near its 52‑week high of $67.94 and carrying a market cap of roughly $3.25 billion.
• Analyst outlook: Several firms have boosted price targets (e.g., Wedbush $85, BTIG $78, Guggenheim $125) and the average target is about $78.90 with mostly Buy ratings, even as consensus shows negative near‑term EPS (≈ -$3.41 for the year).

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) insider Joana Goncalves sold 7,000 shares of the firm's stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $66.12, for a total transaction of $462,840.00. Following the completion of the transaction, the insider directly owned 33,377 shares in the company, valued at approximately $2,206,887.24. The trade was a 17.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Joana Goncalves also recently made the following trade(s):

• On Monday, March 16th, Joana Goncalves sold 7,641 shares of Oruka Therapeutics stock. The shares were sold at an average price of $40.91, for a total transaction of $312,593.31.
• On Tuesday, February 17th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $32.37, for a total transaction of $226,590.00.
• On Thursday, January 15th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $31.81, for a total transaction of $222,670.00.

Oruka Therapeutics Stock Down 2.3%

ORKA stock traded down $1.51 during midday trading on Wednesday, reaching $65.55. The company's stock had a trading volume of 1,402,982 shares, compared to its average volume of 658,507. Oruka Therapeutics, Inc. has a 52 week low of $8.31 and a 52 week high of $67.94. The stock has a market cap of $3.25 billion, a PE ratio of -35.24 and a beta of -0.54. The business's 50-day simple moving average is $41.37 and its 200-day simple moving average is $33.23.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its earnings results on Thursday, March 12th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.16. As a group, equities analysts forecast that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Oruka Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Oruka Therapeutics during the fourth quarter worth $67,000. Seven Fleet Capital Management LP acquired a new stake in shares of Oruka Therapeutics during the fourth quarter worth $159,000. Invesco Ltd. raised its holdings in shares of Oruka Therapeutics by 777.1% during the fourth quarter. Invesco Ltd. now owns 143,121 shares of the company's stock worth $4,338,000 after acquiring an additional 126,803 shares during the period. Virtus Investment Advisers LLC acquired a new stake in shares of Oruka Therapeutics during the fourth quarter worth $267,000. Finally, RTW Investments LP raised its holdings in shares of Oruka Therapeutics by 5.8% during the fourth quarter. RTW Investments LP now owns 2,058,148 shares of the company's stock worth $62,382,000 after acquiring an additional 112,499 shares during the period. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Oruka Therapeutics

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Wedbush raised its price target sharply to $85 and moved to an "outperform" rating, signaling strong upside vs. current levels and providing fresh catalyst for buyer interest. Wedbush raises ORKA PT to $85 (Benzinga)
• Positive Sentiment: HC Wainwright reiterated a "Buy" and $70 price target while publishing detailed quarterly and FY2026–FY2027 EPS forecasts (illustrating the firm's modeling of Oruka's path over the next two years). That continued analyst support is a constructive signal for the stock. HC Wainwright Forecasts Strong Price Appreciation for Oruka Therapeutics (AmericanBankingNews)
• Positive Sentiment: BTIG boosted its price target to $78, adding another independent upward valuation revision that can attract demand from momentum and target‑driven traders. BTIG Research Boosts Oruka Therapeutics Price Target to $78 (AmericanBankingNews)
• Neutral Sentiment: Analyst consensus and sell‑side modeling still show negative EPS for the near term (consensus ~($3.41) for the current fiscal year), underscoring this is a growth/clinical‑stage story where valuation rests on future outcomes rather than current profits. Oruka Therapeutics analyst consensus (MarketBeat)
• Negative Sentiment: Despite the analyst upgrades, the stock is down today on heavier-than-average volume, suggesting short‑term profit‑taking or repositioning by traders following recent strong gains — a risk for near‑term volatility.

Wall Street Analyst Weigh In

Several research firms have weighed in on ORKA. BTIG Research increased their target price on shares of Oruka Therapeutics from $73.00 to $78.00 and gave the stock a "buy" rating in a report on Monday. Guggenheim reiterated a "buy" rating and issued a $125.00 target price on shares of Oruka Therapeutics in a report on Monday. Wall Street Zen upgraded shares of Oruka Therapeutics from a "sell" rating to a "hold" rating in a report on Monday, March 16th. Barclays increased their target price on shares of Oruka Therapeutics from $50.00 to $78.00 and gave the stock an "overweight" rating in a report on Tuesday, April 7th. Finally, Piper Sandler began coverage on shares of Oruka Therapeutics in a report on Thursday, December 18th. They issued an "overweight" rating and a $75.00 target price on the stock. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $78.90.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.